The World Health Organization announced Tuesday it has officially adopted the first-ever "Pandemic Agreement," just as the ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

Pfizer just penned a $6 billion licensing deal with China's 3SBio to develop and commercialize a cancer drug, SSGJ-707. The ...

At a recent gathering, experts in the Swiss biotech and pharma sector underscored the power of international alliances.

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...